Last reviewed · How we verify
Carvedilol alone
Carvedilol alone is a Beta-blocker with alpha-1 antagonist activity Small molecule drug developed by Taipei Veterans General Hospital, Taiwan. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction post-myocardial infarction.
Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking properties that reduces heart rate, blood pressure, and cardiac workload.
Carvedilol is a small molecule that acts as an antagonist to the adrenergic receptor beta. It is used in clinical studies for various conditions including aging, liver cirrhosis, and esophageal and gastric varices.
At a glance
| Generic name | Carvedilol alone |
|---|---|
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Drug class | Beta-blocker with alpha-1 antagonist activity |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and blood vessels. This dual action decreases heart rate and contractility while causing vasodilation, making it effective for managing hypertension and heart failure by reducing cardiac oxygen demand and improving ventricular remodeling.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Left ventricular dysfunction post-myocardial infarction
- Angina pectoris
Common side effects
- Dizziness
- Fatigue
- Hypotension
- Bradycardia
- Hyperglycemia
- Erectile dysfunction
- Bronchospasm
Key clinical trials
- Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension (PHASE2)
- Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices (PHASE4)
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis (PHASE4)
- N-of-1 for Beta-Blockers in Cardiac Amyloidosis (PHASE4)
- CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound (NA)
- Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol alone CI brief — competitive landscape report
- Carvedilol alone updates RSS · CI watch RSS
- Taipei Veterans General Hospital, Taiwan portfolio CI
Frequently asked questions about Carvedilol alone
What is Carvedilol alone?
How does Carvedilol alone work?
What is Carvedilol alone used for?
Who makes Carvedilol alone?
What drug class is Carvedilol alone in?
What development phase is Carvedilol alone in?
What are the side effects of Carvedilol alone?
What does Carvedilol alone target?
Related
- Drug class: All Beta-blocker with alpha-1 antagonist activity drugs
- Target: All drugs targeting Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
- Manufacturer: Taipei Veterans General Hospital, Taiwan — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Left ventricular dysfunction post-myocardial infarction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing